Thermedical® developed new Saline Enhanced Radiofrequency (SERF) ablation system and Durablate catheter for the treatment of Ventricular Tachycardia (VT).
This novel device will treat large volumes of tissue with a single device rather than using the conventional methods.
The device was introduced to treat ventricular tachycardia (VT), a state where rapid heart rhythm leads to sudden cardiac arrest globally. It is estimated than sudden cardiac death ends life of approximately 325,000 US adults annually.
Implantable Cardioverter Defibrillators (ICD) are now presently used to know the condition of patient’s heart rhythm who suffers with VT. In addition, ICD cannot stop or cure the progression of the condition. Hence, Thermedical’s SERF ablation system was introduced which is 20 times more efficient at transferring heat than traditional ablation methods, meeting all the current standard-of-care treatment for VT by enabling a new form of biological heat transfer.
Compared to previous catheters, the Durablate catheter can accurately control the ablation size and treat tissue that is deeper in the heart wall, which is where life-threatening arrhythmias that cause VT are often located.
It is designed to treat underlying diseases with less complicated procedures that increases the safety.
New technology will meet the clear unmet patient needs to deliver aneffective and convenient therapy offering new hope for patients with VT who have fewer options.
